ENFERMEDADES HEPÁTICAS
![Foto de ENFERMEDADES HEPÁTICAS](/img/grupo.png)
![Foto de Mayo Clinic](/img/noimage_org.png)
Mayo Clinic
Rochester, Estados UnidosPublicaciones en colaboración con investigadores/as de Mayo Clinic (23)
2023
-
Metabolic liver cancer: associations of rare and common germline variants in one-carbon metabolism and DNA methylation genes
Human molecular genetics, Vol. 32, Núm. 16, pp. 2646-2655
2022
-
Genetics, pathobiology and therapeutic opportunities of polycystic liver disease
Nature Reviews Gastroenterology and Hepatology, Vol. 19, Núm. 9, pp. 585-604
-
Long non-coding RNA ACTA2-AS1 promotes ductular reaction by interacting with the p300/ELK1 complex
Journal of Hepatology, Vol. 76, Núm. 4, pp. 921-933
2021
-
Epigenomic Evaluation of Cholangiocyte Transforming Growth Factor-β Signaling Identifies a Selective Role for Histone 3 Lysine 9 Acetylation in Biliary Fibrosis
Gastroenterology, Vol. 160, Núm. 3, pp. 889-905.e10
-
Targeting UBC9-mediated protein hyper-SUMOylation in cystic cholangiocytes halts polycystic liver disease in experimental models
Journal of Hepatology, Vol. 74, Núm. 2, pp. 394-406
2020
-
Cholangiocarcinoma 2020: the next horizon in mechanisms and management
Nature Reviews Gastroenterology and Hepatology, Vol. 17, Núm. 9, pp. 557-588
-
Proteostasis disturbances and endoplasmic reticulum stress contribute to polycystic liver disease: New therapeutic targets
Liver International, Vol. 40, Núm. 7, pp. 1670-1685
2018
-
Cholangiocytes in health and disease: From basic science to novel treatments
Biochimica et Biophysica Acta - Molecular Basis of Disease
-
MicroRNA (miR)-433 and miR-22 dysregulations induce histone-deacetylase-6 overexpression and ciliary loss in cholangiocarcinoma
Hepatology, Vol. 68, Núm. 2, pp. 561-573
-
MicroRNA-506 promotes primary biliary cholangitis–like features in cholangiocytes and immune activation
Hepatology, Vol. 67, Núm. 4, pp. 1420-1440
2017
-
New potential targets for the treatment of biliary diseases
Current Drug Targets
-
SOX17 regulates cholangiocyte differentiation and acts as a tumor suppressor in cholangiocarcinoma
Journal of Hepatology, Vol. 67, Núm. 1, pp. 72-83
-
Serum extracellular vesicles contain protein biomarkers for primary sclerosing cholangitis and cholangiocarcinoma
Hepatology, Vol. 66, Núm. 4, pp. 1125-1143
2016
-
Mutations in GANAB, Encoding the Glucosidase IIα Subunit, Cause Autosomal-Dominant Polycystic Kidney and Liver Disease
American Journal of Human Genetics, Vol. 98, Núm. 6, pp. 1193-1207
2015
-
Ursodeoxycholic acid inhibits hepatic cystogenesis in experimental models of polycystic liver disease
Journal of Hepatology, Vol. 63, Núm. 4, pp. 952-961
2014
-
Centrosomal abnormalities characterize human and rodent cystic cholangiocytes and are associated with Cdc25A overexpression
American Journal of Pathology, Vol. 184, Núm. 1, pp. 110-121
-
Inhibition of metalloprotease hyperactivity in cystic cholangiocytes halts the development of polycystic liver diseases
Gut, Vol. 63, Núm. 10, pp. 1658-1667
2013
-
Alcohol consumption on pancreatic diseases
World Journal of Gastroenterology, Vol. 19, Núm. 5, pp. 638-647
-
Efficient recovery of proteins from multiple source samples after trizol® or trizol®LS RNA extraction and long-term storage
BMC Genomics, Vol. 14, Núm. 1
-
Pasireotide is more effective than octreotide in reducing hepatorenal cystogenesis in rodents with polycystic kidney and liver diseases
Hepatology, Vol. 58, Núm. 1, pp. 409-421